Retatrutide Side Effects: What Clinical Studies Actually Show

Overview of the Safety Data

Retatrutide has been tested in Phase 1 and Phase 2 clinical trials involving several hundred participants. That is a solid body of early-stage data, but the full safety profile of any investigational drug only becomes clear through larger Phase 3 trials and post-marketing surveillance. Below is a summary of what the published clinical data show so far.

The Phase 1 and Phase 2 trials showed no unexpected or new safety signals. The side effects were broadly in line with other incretin-based therapies, and gastrointestinal effects were the most common. The Phase 3 TRIUMPH-4 trial later identified a new signal, dysesthesia (see below).

Gastrointestinal Effects: The Primary Concern

As with all GLP-1 receptor agonists and related multi-receptor agonists, gastrointestinal side effects were the most often reported in retatrutide trials. The main GI events were:

• Nausea: The most common adverse event. In the Phase 2 obesity trial it was reported by 14% to 60% of participants depending on dose and starting dose (45% at 12 mg), against 11% on placebo. Nausea was most frequent in the first weeks of treatment and during dose increases.
• Diarrhea: Reported by 9% to 20% of retatrutide groups (15% at 12 mg), against 11% on placebo.
• Vomiting: Occurred in 3% to 26% of retatrutide groups (19% at 12 mg), against 1% on placebo.
• Decreased appetite: Although lower appetite is partly how the drug works, some participants reported it as an adverse event.
• Constipation and dyspepsia: Less frequent but present across dose groups.

The key context is that most GI side effects were mild to moderate. Most happened during dose escalation and tended to ease as participants reached their maintenance dose.

Dose-Dependent Patterns

The Phase 2 obesity trial clearly showed that side effects became more common at higher doses:

At the 1 mg dose, GI adverse events were relatively infrequent, and 7% of participants stopped because of adverse events. At the 4 mg escalating dose, GI events were more common but remained manageable for most participants. At the 8 mg and 12 mg doses, GI adverse event rates were highest, though still within the range observed for other approved incretin therapies.

Side effects rise with dose in the same way efficacy does, which creates a trade-off between getting the most benefit and keeping the drug tolerable.

The Importance of Dose Escalation

One of the most informative findings from Phase 2 was the comparison between the two 4 mg groups, one starting at 2 mg and one starting at 4 mg. Participants who started at 2 mg and moved up to 4 mg had about half as much nausea (18% vs 36%) as those who began at the full 4 mg dose. The gap was wider in the two 8 mg groups (17% vs 60%).

This finding directly shaped the dose-escalation schedules used in the Phase 3 TRIUMPH program. Raising the dose gradually gives the gut time to adapt to incretin receptor stimulation, so nausea and other GI effects are milder and less frequent. The clinical lesson is clear: starting low and going up slowly is essential to making retatrutide tolerable.

Discontinuation Rates

Discontinuation due to adverse events is one of the most meaningful safety measures, because it captures side effects bad enough to make patients stop treatment altogether. In the Phase 2 obesity trial:

• Placebo: 0%
• 1 mg: 7%
• 4 mg (2 mg start): 6%
• 4 mg (4 mg start): 9%
• 8 mg (2 mg start): 14%
• 8 mg (4 mg start): 6%
• 12 mg: 16%

The 16% discontinuation rate at the highest dose is notable and deserves attention. For context, the US labels report 6.8% for semaglutide 2.4 mg and 4.8% to 6.7% for tirzepatide, depending on dose. Whether optimized escalation protocols in Phase 3 will reduce retatrutide’s discontinuation rate remains to be determined.

Non-GI Adverse Events

Beyond gastrointestinal effects, the clinical data showed no significant safety concerns:

• Injection site reactions were infrequent and mild, consistent with other subcutaneous peptide therapies.
• Heart rate increases were small and dose-dependent, a known class effect of GLP-1 receptor agonists.
• No clinically significant pancreatitis, thyroid, or gallbladder signals emerged, though these are monitored carefully in ongoing trials given the known class considerations for incretin-based therapies.
• Glycemic parameters improved across groups, with no clinically significant hypoglycemia in participants without diabetes.

Phase 3 TRIUMPH-4 Safety Data (December 2025)

The Phase 3 TRIUMPH-4 trial provided a much larger safety dataset. It confirmed that side effects rose with dose, as in Phase 2, and it also turned up new findings.

Updated GI Rates

TRIUMPH-4 GI adverse event rates at the 12 mg dose, over 68 weeks, compared with the 12 mg group of the 48-week Phase 2 trial:

• Nausea: 43.2% (Phase 2: 45%)
• Diarrhea: 33.1% (Phase 2: 15%)
• Vomiting: 20.9% (Phase 2: 19%)

Nausea and vomiting were similar; diarrhea was more common. These rates are broadly comparable to those in the Wegovy (semaglutide 2.4 mg) label (nausea 44%, diarrhea 30%, vomiting 24%) and remain consistent with the incretin-based therapy class.

Dysesthesia: A New Safety Signal

TRIUMPH-4 identified dysesthesia (abnormal sensations such as tingling, numbness or burning) as a new safety signal that had not stood out in Phase 2 data. Rates were clearly dose-dependent:

• Placebo: 0.7%
• 9 mg: 8.8%
• 12 mg: 20.9%

Dysesthesia was generally mild and infrequently led to treatment discontinuation. The signal is thought to be linked to glucagon receptor activity, which distinguishes retatrutide from GLP-1-only and dual GIP/GLP-1 agonists. This is an important finding: it is a side effect not seen with other incretin-based therapies, and it will need monitoring in ongoing trials and after approval.

Phase 3 Discontinuation Rates

Treatment discontinuation due to adverse events in TRIUMPH-4:

• Placebo: 4.0%
• 9 mg: 12.2%
• 12 mg: 18.2%

The 18.2% discontinuation rate at the 12 mg dose is modestly higher than the 16% seen in Phase 2, and higher than the 6.8% in the semaglutide 2.4 mg label and the 4.8% to 6.7% in the tirzepatide (Zepbound) label. In the later TRIUMPH-1 trial it was 11.3% at 12 mg. Whether better dose escalation can bring this rate down is still an open question.

What Remains to Be Determined

Since TRIUMPH-4, the later Phase 3 trials (TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, TRANSCEND-T2D-1 and TRANSCEND-T2D-2) have added safety data in people with obesity, type 2 diabetes and cardiovascular disease; dysesthesia at 12 mg was lower than in TRIUMPH-4, at 12.5% in TRIUMPH-1, 7.3% in TRIUMPH-2 and 6.4% in TRIUMPH-3. Several questions remain. Long-term safety beyond 80 weeks, effects in special populations, and the full characterization of the dysesthesia signal all require continued study. Retatrutide’s safety profile is no longer purely preliminary, since Phase 3 data are now available. It is still incomplete compared with approved therapies that have years of post-marketing surveillance behind them.